These terms govern your use of prox-ai.com and our first exchanges with you. Any engagement is governed by a signed agreement, which prevails over these terms.
ProxAI provides de novo protein design services. All computational outputs are predictions. They require experimental validation, in the ProxAI wet lab or at a partner facility, before any therapeutic claim can be substantiated.
The intake form and the first scoping call are pre-NDA and non-confidential. Share only non-confidential target information at this stage.
If you ask for one, we return a mutual NDA within two business days, before any sequence or structure is exchanged.
Rights to the designs, sequences and data generated in an engagement are set out in the engagement agreement. Submitting a target through this site does not transfer any rights in either direction.
Timelines on this site (for example, 12 to 15 weeks from intake to handover) are typical estimates, not commitments. Each program’s schedule is fixed in its design brief.
Drug discovery is inherently high-risk. ProxAI does not guarantee successful binder generation for every target, particularly targets with high conformational flexibility or low-surface-area interfaces.
This site is for general information only. It is not an offer, and it is not medical advice. It is provided as is, and to the extent the law allows, ProxAI is not liable for decisions made on the basis of its content.
The ProxAI name, logo, text and images belong to ProxAI and may not be reused without permission.
These terms are governed by the laws of Québec and the federal laws of Canada that apply there. Any dispute goes before the courts of the district of Montréal.
Write to info@prox-ai.com and a member of the scientific team will reply.
